Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Junlong Wu

Showing results (111-120 of 124) with videos related to

Pageof 13
Sort By:
Molecular Cancer|March 20, 2024
Clinical effectiveness of a multitarget urine DNA test for urothelial carcinoma detection: a double-blinded, multicenter, prospective trialJunlong Wu, Yuda Lin, Kaiwei Yang, et al.
Cell Reports. Medicine|January 11, 2023
Inherited mutations in Chinese patients with upper tract urothelial carcinomaJunlong Wu, Shengming Jin, Chengyuan Gu, et al.
Therapeutic Advances in Medical Oncology|January 8, 2024
Nomogram to predict the presence of PSMA-negative but FDG-positive lesion in castration-resistant prostate cancer: a multicenter cohort studyJian Pan, Tingwei Zhang, Shouzhen Chen, et al.
European Journal of Nuclear Medicine and Molecular Imaging|April 16, 2025
Homologous recombination repair gene alteration is strongly associated with more prostate-specific membrane antigen-positive metastases in newly diagnosed hormone-sensitive prostate cancer with ≤5 conventional imaging defined distant metastasesJian Pan, Bin Zhu, Junlong Wu, et al.
Medcomm|January 19, 2026
Noninvasive Early Detection and Recurrence Monitoring for Non-Muscle-Invasive Bladder Cancer via Urine Tumor DNA: A Prospective Clinical StudyJunlong Wu, Shengming Jin, Qianming Bai, et al.
Transfusion|December 15, 2017
Plerixafor and granulocyte-colony-stimulating factor for mobilization of hematopoietic stem cells for autologous transplantation in Chinese patients with non-Hodgkin's lymphoma: a randomized Phase 3 studyJun Zhu, Huiqiang Huang, Huan Chen, et al.
Molecular Cancer|February 4, 2023
Letter to the Editor: clinical utility of urine DNA for noninvasive detection and minimal residual disease monitoring in urothelial carcinomaKaiwei Yang, Hailong Hu, Junlong Wu, et al.
Clinical and Translational Medicine|September 13, 2023
Development and validation of a nomogram (APGRC) to predict the presence of germline DNA damage repair pathogenic variants in Asian patients with prostate cancerTingwei Zhang, Yu Wei, Boon Hao Hong, et al.
Journal of the National Comprehensive Cancer Network : JNCCN|October 15, 2021
Inherited Mutations in Chinese Men With Prostate CancerYao Zhu, Yu Wei, Hao Zeng, et al.
BMC Medicine|February 20, 2026
First-in-human phase 1/2a study of T3011, an oncolytic HSV expressing IL-12 and PD-1 antibody, administered via intratumoral (IT) injection as monotherapy in advanced solid tumors, including recurrent or metastatic HNSCCDongmei Ji, Wenmin Fu, Yonghong Liu, et al.
Pageof 13

Showing results (111-120 of 124) with videos related to

Sort By:
Pageof 13
Molecular Cancer|March 20, 2024
Clinical effectiveness of a multitarget urine DNA test for urothelial carcinoma detection: a double-blinded, multicenter, prospective trialJunlong Wu, Yuda Lin, Kaiwei Yang, et al.
Cell Reports. Medicine|January 11, 2023
Inherited mutations in Chinese patients with upper tract urothelial carcinomaJunlong Wu, Shengming Jin, Chengyuan Gu, et al.
Therapeutic Advances in Medical Oncology|January 8, 2024
Nomogram to predict the presence of PSMA-negative but FDG-positive lesion in castration-resistant prostate cancer: a multicenter cohort studyJian Pan, Tingwei Zhang, Shouzhen Chen, et al.
European Journal of Nuclear Medicine and Molecular Imaging|April 16, 2025
Homologous recombination repair gene alteration is strongly associated with more prostate-specific membrane antigen-positive metastases in newly diagnosed hormone-sensitive prostate cancer with ≤5 conventional imaging defined distant metastasesJian Pan, Bin Zhu, Junlong Wu, et al.
Medcomm|January 19, 2026
Noninvasive Early Detection and Recurrence Monitoring for Non-Muscle-Invasive Bladder Cancer via Urine Tumor DNA: A Prospective Clinical StudyJunlong Wu, Shengming Jin, Qianming Bai, et al.
Transfusion|December 15, 2017
Plerixafor and granulocyte-colony-stimulating factor for mobilization of hematopoietic stem cells for autologous transplantation in Chinese patients with non-Hodgkin's lymphoma: a randomized Phase 3 studyJun Zhu, Huiqiang Huang, Huan Chen, et al.
Molecular Cancer|February 4, 2023
Letter to the Editor: clinical utility of urine DNA for noninvasive detection and minimal residual disease monitoring in urothelial carcinomaKaiwei Yang, Hailong Hu, Junlong Wu, et al.
Clinical and Translational Medicine|September 13, 2023
Development and validation of a nomogram (APGRC) to predict the presence of germline DNA damage repair pathogenic variants in Asian patients with prostate cancerTingwei Zhang, Yu Wei, Boon Hao Hong, et al.
Journal of the National Comprehensive Cancer Network : JNCCN|October 15, 2021
Inherited Mutations in Chinese Men With Prostate CancerYao Zhu, Yu Wei, Hao Zeng, et al.
BMC Medicine|February 20, 2026
First-in-human phase 1/2a study of T3011, an oncolytic HSV expressing IL-12 and PD-1 antibody, administered via intratumoral (IT) injection as monotherapy in advanced solid tumors, including recurrent or metastatic HNSCCDongmei Ji, Wenmin Fu, Yonghong Liu, et al.
Pageof 13